Confirmation of the Fas counterattack in host-tumor relations

F Shanahan et al. Gastroenterology. 1997 Nov.

. 1997 Nov;113(5):1804-6.

doi: 10.1053/gast.1997.v113.agast971131804.

No abstract available

Similar articles

The Fas counterattack: cancer as a site of immune privilege.
O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. O'Connell J, et al. Immunol Today. 1999 Jan;20(1):46-52. doi: 10.1016/s0167-5699(98)01382-6. Immunol Today. 1999. PMID: 10081230 Review. No abstract available.
Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S, Toomey D, Condron C, Bouchier-Hayes D. Maher S, et al. Immunol Cell Biol. 2002 Apr;80(2):131-7. doi: 10.1046/j.1440-1711.2002.01068.x. Immunol Cell Biol. 2002. PMID: 11940113 Review.
Fas ligand--caught between Scylla and Charybdis.
Strasser A, O'Connor L. Strasser A, et al. Nat Med. 1998 Jan;4(1):21-2. doi: 10.1038/nm0198-021. Nat Med. 1998. PMID: 9427600 No abstract available.
Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease.
Kaplan D, Sieg S. Kaplan D, et al. J Virol. 1998 Aug;72(8):6279-82. doi: 10.1128/JVI.72.8.6279-6282.1998. J Virol. 1998. PMID: 9658065 Free PMC article. Review. No abstract available.
Tumor counterattack: fact or fiction?
Igney FH, Krammer PH. Igney FH, et al. Cancer Immunol Immunother. 2005 Nov;54(11):1127-36. doi: 10.1007/s00262-005-0680-7. Epub 2005 May 12. Cancer Immunol Immunother. 2005. PMID: 15889255 Free PMC article. Review.